Olanzapine monotherapy is effective as treatment for mania in both responders and non-responders to other mood stabilisers. The efficacy of olanzapine for patients who have both responded and failed to respond to other mood stabilising drugs is explored in this secondary analysis of a placebo-controlled trial of olanzapine’s efficacy in acute mania. Robert W Baker and colleagues from Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana and Payne Whitney Clinic, New York Hospital, Cornell University Medical College, New York, United States did this work. Participants in the four-week double blind placebo controlled trial were hospitalised patients in acute manic or mixed bipolar episodes. They received olanzapine monotherapy in doses ranging from 5 mg/day to 20 mg/day. The patients on olanzapine experienced significantly greater improvement in Young-Mania Rating Scale total score and higher remission rates relative to placebo-treated patients, as reported earlier.
סל התרופות כמו אקמול לחולה סרטן/ מאמר אורח מאת ד”ר אודי פרישמן
אין תגובות06/01/2020
מדי שנה רועשת וגועשת התקשורת סביב סל התרופות, מה ייכנס
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!